Skip to content

Study · In vitro (cells) · 1999

3 results

Somatostatin and its analog lanreotide inhibit the proliferation of dispersed human non-functioning pituitary adenoma cells in vitro.

Florio T, Thellung S, Arena S, Corsaro A, Spaziante R, Gussoni G, Acuto G, Giusti M, Giordano G, Schettini G

European journal of endocrinology1 Oct 1999Cited by 58 (Europe PMC)

PMID10526255 (opens in a new tab)DOI10.1530/eje.0.1410396 (opens in a new tab)PepBankPUB-10526255
Source linkPubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

2 results from studies that gave the peptide. No result from this study comes from people.

  1. 01LabIn vitro (cells)Efficacy outcome

    In human non-functioning pituitary adenoma cells, lanreotide inhibited PMA-induced proliferation.

    In plain wordsIn cells from human pituitary tumors, lanreotide reduced proliferation induced by PMA.

    Peptide
    Lanreotide
    Outcome
    DecreasePMA-induced proliferation
    Study

    humann: not reported in source

    Cultured non-functioning pituitary adenoma cells
    Comparator
    PMA stimulation
    Outcome group
    Tumor growth · Endocrine and hormones
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Somatostatin and lanreotide treatment inhibited phorbol myristate acetate (PMA)-induced cell proliferation.
    1 context sentence
    Summary · context
    Twenty-three NFPA post-surgical specimens were analyzed for somatostatin receptor (SSTR) expression and 12 of them were cultured in vitro to study somatostatin's effects on cell proliferation, assessed by means of [(3)H]thymidine uptake, and the intracellular signaling.
  2. 02LabIn vitro (cells)Mechanism

    In human non-functioning pituitary adenoma cells, lanreotide significantly inhibited calcium channel activity induced by 40mmol/l K(+) depolarization.

    In plain wordsIn cells from human pituitary tumors, lanreotide reduced calcium channel activity induced by potassium depolarization.

    Peptide
    Lanreotide
    Outcome
    DecreaseVoltage-sensitive calcium channel activity
    Study

    humann: not reported in source

    Cultured non-functioning pituitary adenoma cells
    Comparator
    40mmol/l K(+) depolarization
    Outcome group
    Receptor activity and mechanism · Endocrine and hormones
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Somatostatin and lanreotide caused also a significant inhibition of voltage-sensitive calcium channel activity induced by 40mmol/l K(+) depolarization in microfluorimetric analysis.
    1 context sentence
    Summary · context
    Twenty-three NFPA post-surgical specimens were analyzed for somatostatin receptor (SSTR) expression and 12 of them were cultured in vitro to study somatostatin's effects on cell proliferation, assessed by means of [(3)H]thymidine uptake, and the intracellular signaling.

Studies that did not test the peptide alone1

In this study, Lanreotide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Lanreotide.

  1. 03LabNot a test of Lanreotide aloneIn vitro (cells)Mechanism

    In human non-functioning pituitary adenoma cells, vanadate pretreatment reversed lanreotide inhibition of PMA-induced DNA synthesis.

    In plain wordsIn cells from human pituitary tumors, vanadate pretreatment reversed lanreotide's inhibition of PMA-induced DNA synthesis.

    Peptide
    Lanreotide
    Outcome
    MixedVanadate reversal of DNA synthesis inhibition
    Study

    humann: not reported in source

    Cultured non-functioning pituitary adenoma cells
    Comparator
    Lanreotide without vanadate pretreatment
    Outcome group
    Receptor activity and mechanism · Endocrine and hormones

    Source sentences

    Summary
    Vanadate pretreatment reversed somatostatin and lanreotide inhibition of PMA-induced DNA synthesis suggesting an involvement of tyrosine phosphatase in this effect.
    1 context sentence
    Summary · context
    Twenty-three NFPA post-surgical specimens were analyzed for somatostatin receptor (SSTR) expression and 12 of them were cultured in vitro to study somatostatin's effects on cell proliferation, assessed by means of [(3)H]thymidine uptake, and the intracellular signaling.

    In this study, Lanreotide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Lanreotide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:36 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.